Eesti - eesti - Ravimiamet

portfarma ehf. - estsitalopraam - õhukese polümeerikattega tablett - 10mg 14tk; 10mg 500tk; 10mg 98tk; 10mg 30tk; 10mg 56tk; 10mg 100tk; 10mg 20tk; 10mg 28tk; 10mg 50tk

Eesti - eesti - Ravimiamet

norameda uab - estsitalopraam - õhukese polümeerikattega tablett - 20mg 100tk; 20mg 20tk; 20mg 56tk; 20mg 28tk; 20mg 14tk; 20mg 30tk; 20mg 50tk

Eesti - eesti - Ravimiamet

norameda uab - estsitalopraam - õhukese polümeerikattega tablett - 10mg 14tk; 10mg 28tk; 10mg 30tk; 10mg 56tk; 10mg 20tk; 10mg 50tk

Eesti - eesti - Ravimiamet

portfarma ehf. - estsitalopraam - õhukese polümeerikattega tablett - 20mg 50tk; 20mg 500tk; 20mg 98tk; 20mg 30tk; 20mg 100tk

Eesti - eesti - Ravimiamet

zentiva k.s. - estsitalopraam - õhukese polümeerikattega tablett - 10mg 60tk

Eesti - eesti - Ravimiamet

gedeon richter plc. - paroksetiin - õhukese polümeerikattega tablett - 20mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - dapagliflosiin - õhukese polümeerikattega tablett - 10mg 98tk; 10mg 28tk; 10mg 100tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - dapagliflosiin - õhukese polümeerikattega tablett - 5mg 98tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - dapaglifloksiinpropaandioolmonohüdraat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. lisaks teiste ravimitega ravi 2. tüüpi diabeedi. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.